SDBN Blog, News

Life Science Events, Jobs, Directory, News

 

Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
2026-04-02 13:05 UTC by SDBN

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will showcase new data on CLD-401, a systemically delivered oncolytic virus that is designed to express high levels of IL-15 superagonist (“IL-15 SA”) only in the tumor microenvironment (“TME”), currently in IND-enabling studies.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


 

Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative.